3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Hepatocellular
11
Stomach Neoplasms
6
Carcinoma, Non-Small-Cell Lung
3
Ovarian Neoplasms
2
Gastric Adenocarcinoma
2
Esophageal Squamous Cell Carcinoma
2
Cholangiocarcinoma
2
Breast Neoplasms
2
Biliary Tract Neoplasms
2
Advanced Gastric Cancer
2
Adenocarcinoma
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Radioactive Iodine-refractory Differentiated Thyroid Cancer
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Malignant Neoplasms of Digestive Organs
1
Liver Neoplasms
1
Gestational Trophoblastic Disease
1
Gastrointestinal Stromal Tumors
1
Fludzoparib" and Anti-angiogenic
1
Colonic Neoplasms
1
Cirrhosis, Familial, with Pulmonary Hypertension
1
Advanced Primary Liver Cancer
1
Advanced Biliary Tract Carcinoma
1
Adebrelimab
1
Interventions
lutetium Lu 177 dotatate
21
Magnetic Resonance Spectroscopy
10
pembrolizumab
9
Specimen Handling
7
Everolimus
7
cabozantinib
6
Nivolumab
6
lenvatinib
5
Capecitabine
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
surufatinib
4
olaparib
4
amino-acid, glucose, and electrolyte solution
4
lanreotide
3
atezolizumab
3
Temozolomide
3
Octreotide
3
Lutetium-177
3
Ipilimumab
3
Injections
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
X-Rays
2
Radiotherapy
2
Phantoms, Imaging
2
PM 01183
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
apatinib
×
1 year
×
Clear all
No trials found.